Actively Recruiting
PET Targeting Acid Phosphatase 3 (ACP3) in Prostate Cancer Compared With 68Ga-PSMA PET/CT
Led by The First Affiliated Hospital of Xiamen University · Updated on 2025-11-21
60
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating a new imaging approach using 68Ga-XACP3 PET/CT to detect tumor lesions in men with prostate cancer. This study compares the diagnostic performance of 68Ga-XACP3 PET/CT with the current standard imaging method, 68Ga-PSMA PET/CT, aiming to improve detection of initial or recurrent prostate cancer lesions. The study is led by The First Affiliated Hospital of Xiamen University. Participants receive a single intravenous injection of both 68Ga-XACP3 and 68Ga-PSMA radiotracers, followed by PET/CT imaging within a designated time frame. The study records tumor uptake using maximum standard uptake value (SUVmax) and counts the number of positive tumor lesions detected by both imaging methods. Diagnostic accuracy of 68Ga-XACP3 will be calculated and compared to 68Ga-PSMA. During the study, participants undergo both PET/CT scans and clinical assessments to evaluate tumor detection. Researchers will measure diagnostic efficacy over one year, focusing on the number of lesions identified and SUV values. Participants must provide informed consent, and safety and imaging results will be monitored throughout the study period, which runs until October 2027.
CONDITIONS
Brief Title
68Ga-XACP3 PET/CT in Prostate Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients aged 18 years or older
- Diagnosed with prostate cancer or highly suspected recurrence or previously treated metastases
- Scheduled for both 68Ga-PSMA PET/CT and 68Ga-XACP3 PET/CT scans
- Able to provide informed consent and assent according to ethics guidelines
You will not qualify if you...
- Unable or unwilling to provide written informed consent by participant or legal representative
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Single day
Participants receive a single intravenous injection of 68Ga-XACP3 and standard-of-care radiopharmaceuticals and undergo PET/CT imaging for prostate cancer assessment.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China, 361000
Actively Recruiting
Research Team
L
Liang Zhao
H
Haojun Chen, MD, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here